Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Patients with schizophrenia or bipolar disorder can now treat agitation at home. The FDA has approved Igalmi (dexmedetomidine) 120mcg sublingual film for unsupervised at-home use in non-geriatric adults without hepatic impairment — making it the first FDA-approved at-home acute agitation treatment. Phase 3 data showed successful self-administration, good tolerability, and significantly greater full symptom resolution versus placebo.
Agitation relief, now at home. The FDA has approved Igalmi® (dexmedetomidine), a sublingual film and alpha-2 adrenergic receptor agonist, for unsupervised at-home use in adults experiencing acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. Previously, Igalmi could only be administered under healthcare provider supervision due to risks of hypotension, bradycardia, and falls.
The approval was supported by the phase 3 SERENITY At-Home study, which enrolled 246 patients on stable treatment who self-administered Igalmi 120mcg or placebo during real-world agitation episodes. All participants successfully self-administered the film, and the drug was well tolerated — with no discontinuations, serious adverse events, syncopes, or falls reported.
By the Numbers:
Why it matters: For patients who experience agitation episodes outside clinical settings, this approval fills a critical gap — offering a fast-acting, self-administered option that can be used when and where it's needed most, potentially reducing ER visits and caregiver burden.